Insulin receptor antibody-iduronate 2-sulfatase fusion protein: Pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys

ABSTRACT Mucopolysaccharidosis (MPS) Type II is caused by mutations in the gene encoding the lysosomal enzyme, iduronate 2‐sulfatase (IDS). The majority of MPSII cases affect the brain. However, enzyme replacement therapy with recombinant IDS does not treat the brain, because IDS is a large molecule...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biotechnology and bioengineering 2014-11, Vol.111 (11), p.2317-2325
Hauptverfasser:	Boado, Ruben J., Ka-Wai Hui, Eric, Zhiqiang Lu, Jeff, Pardridge, William M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - genetics Antibodies, Monoclonal - pharmacokinetics Antigens, CD - immunology blood-brain barrier Brain drug delivery Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Enzymes Glycoproteins - administration & dosage Glycoproteins - adverse effects Glycoproteins - genetics Glycoproteins - pharmacokinetics Infusions, Intravenous Insulin lysosomal enzyme Macaca mulatta Metabolic Clearance Rate Monkeys Monkeys & apes Monoclonal antibodies monoclonal antibody Mutation Pharmacology Plasma - chemistry Proteins Receptor, Insulin - immunology Receptors Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - pharmacokinetics Shear stress Tissue engineering Transport
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!